Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy company focused on oncology, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. The event will take place from August 13-15, 2024 at the InterContinental Boston Hotel.
Chief Medical Officer Dr. Thomas Heineman will engage in a fireside chat on Tuesday, August 13, 2024, at 8:30 a.m. ET in the Hutchinson Room. The presentation will be accessible via webcast on the company's Investor Relations page.
Additionally, Oncolytics' management team will be available for one-on-one investor meetings during the conference. Interested parties can schedule meetings through the conference website, Canaccord representatives, or by emailing jpatton@oncolytics.ca.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), un'azienda di immunoterapia in fase clinica focalizzata sull'oncologia, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. L'evento si svolgerà dal 13 al 15 agosto 2024 presso l'InterContinental Boston Hotel.
Il Direttore Medico Dr. Thomas Heineman parteciperà a una chiacchierata informale il martedì 13 agosto 2024, alle 08:30 ET nella Hutchinson Room. La presentazione sarà accessibile tramite webcast sulla pagina delle Relazioni con gli Investitori dell'azienda.
Inoltre, il team di gestione di Oncolytics sarà disponibile per incontri individuali con gli investitori durante la conferenza. Le parti interessate possono programmare incontri attraverso il sito web della conferenza, i rappresentanti di Canaccord, o inviando un'email a jpatton@oncolytics.ca.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), una compañía de inmunoterapia en etapa clínica centrada en la oncología, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El evento se llevará a cabo del 13 al 15 de agosto de 2024 en el InterContinental Boston Hotel.
El Director Médico Dr. Thomas Heineman participará en una charla informal el martes 13 de agosto de 2024, a las 08:30 a.m. ET en el Hutchinson Room. La presentación será accesible a través de una transmisión web en la página de Relaciones con Inversores de la empresa.
Además, el equipo de gestión de Oncolytics estará disponible para reuniones individuales con inversores durante la conferencia. Las partes interesadas pueden programar reuniones a través del sitio web de la conferencia, los representantes de Canaccord, o enviando un correo electrónico a jpatton@oncolytics.ca.
온콜리틱스 바이오텍 주식회사 (NASDAQ: ONCY) (TSX: ONC)는 종양학에 초점을 맞춘 임상 단계의 면역 요법 회사로, 캐나다 금융그룹의 제44회 연례 성장 콘퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 8월 13일부터 15일까지 인터콘티넨탈 보스턴 호텔에서 개최됩니다.
최고 의학 책임자 Dr. Thomas Heineman는 2024년 8월 13일 화요일 오전 8:30 ET에 허치슨 룸에서 대화형 채팅에 참석할 예정입니다. 발표는 회사의 투자자 관계 페이지를 통해 웹캐스트로 제공됩니다.
또한, 온콜리틱스의 관리팀은 콘퍼런스 기간 동안 개별 투자자 회의를 위해 대기할 것입니다. 관심 있는 분들은 콘퍼런스 웹사이트, 캐나다 금융그룹의 대표, 또는 jpatton@oncolytics.ca로 이메일을 통해 회의를 예약할 수 있습니다.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), une entreprise de traitement immunologique en phase clinique axée sur l'oncologie, a annoncé sa participation à la 44ème Conférence Annuelle sur la Croissance de Canaccord Genuity. L'événement se déroulera du 13 au 15 août 2024 à l'hôtel InterContinental de Boston.
Le directeur médical Dr. Thomas Heineman participera à une discussion informelle le mardi 13 août 2024, à 8h30 ET dans la salle Hutchinson. La présentation sera accessible par webdiffusion sur la page des Relations avec les Investisseurs de l'entreprise.
De plus, l'équipe de direction d'Oncolytics sera disponible pour des réunions individuelles avec des investisseurs pendant la conférence. Les parties intéressées peuvent planifier des réunions via le site de la conférence, par l'intermédiaire des représentants de Canaccord ou en envoyant un courriel à jpatton@oncolytics.ca.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), ein klinisch tätiges Unternehmen für Immuntherapie mit Schwerpunkt auf Onkologie, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity bekannt gegeben. Die Veranstaltung findet vom 13. bis 15. August 2024 im InterContinental Boston Hotel statt.
Der Chief Medical Officer Dr. Thomas Heineman wird am Dienstag, den 13. August 2024, um 8:30 Uhr ET im Hutchinson Room an einem informellen Gespräch teilnehmen. Die Präsentation wird über ein Webcast auf der Investor-Relations-Seite des Unternehmens zugänglich sein.
Zusätzlich wird das Management-Team von Oncolytics während der Konferenz für Einzelgespräche mit Investoren zur Verfügung stehen. Interessierte Parteien können Meetings über die Konferenz-Website, über Canaccord-Vertreter oder per E-Mail an jpatton@oncolytics.ca planen.
- None.
- None.
Date: Tuesday, August 13, 2024
Time: 8:30 a.m. ET
Location: InterContinental
Webcast Link: Available by clicking here
Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your Canaccord representative, or email jpatton@oncolytics.ca.
A live webcast of the Company's presentation will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for three months.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
Logo : https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-participate-in-a-fireside-chat-at-canaccord-genuitys-44th-annual-growth-conference-302213197.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When is Oncolytics Biotech (ONCY) participating in Canaccord Genuity's 44th Annual Growth Conference?
Who will represent Oncolytics Biotech (ONCY) at the Canaccord Genuity conference?
Where can investors access the webcast of Oncolytics Biotech's (ONCY) presentation?
How can investors schedule one-on-one meetings with Oncolytics Biotech (ONCY) management at the conference?
